MedPath

Evaluation the effect of the adjunctive use of red CoQ10 on the results of non-surgical periodontal treatment

Phase 4
Conditions
chronic periodontitis.
Chronic periodontitis
K05.3
Registration Number
IRCT20230615058492N1
Lead Sponsor
Yazd University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
40
Inclusion Criteria

1. The amount of clinical attachment loss is 3 mm or more
The age of the patient is between 25-60
3. The patient should be systemically healthy (such as not suffering from diabetes, high blood pressure or liver problems)

Exclusion Criteria

History of periodontal treatment during the last 6 months
Presence of disease or systemic conditions that interfere with wound healing.
Pregnant or lactating patient
smoking
The patient is undergoing radiotherapy or chemotherapy
Taking drugs that affect the periodontium, such as anticonvulsants, calcium channel blockers
Taking blood lipid-lowering drugs that reduce Coenzyme Q10, such as statins ( lovastatin and atorvastatin)
Taking vitamin A, vitamin E and Coenzyme Q10 supplements during the last three months
Taking warfarin or clopidogrel because some studies indicate the interaction of Coenzyme Q10 with anticoagulant drugs.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Probing depth. Timepoint: At the beginning of the study and 6 weeks after the start of red CoQ10 consumption. Method of measurement: Williams periodontal probe.
Secondary Outcome Measures
NameTimeMethod
Clinical attachment loss. Timepoint: At the beginning of the study and 6 weeks after the start of red CoQ10 consumption. Method of measurement: Williams periodontal probe.;Bleeding on probing. Timepoint: At the beginning of the study and 6 weeks after the start of red CoQ10 consumption. Method of measurement: Williams periodontal probe.
© Copyright 2025. All Rights Reserved by MedPath